Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg…
The benefit-risk assessment of cancer treatments usually focuses on traditional clinical and disease outcomes, such as overall survival, progression-free survival, and tumour response, balanced against…
The health insurance system in Japan faces political manoeuvring ahead of the House of Councillors elections in July, 2025.
These results support the safety and potential antitumour activity of inhibiting the immune checkpoint CISH through the administration of neoantigen-reactive CISH-knockout TILs, with implications for…
In this global cohort of BRCA carriers with previous breast cancer diagnosis at a young age, RRM and RRSO were both associated with a significant…
Anlotinib plus penpulimab significantly improved progression-free survival and overall survival versus sorafenib in unresectable HCC and might be a new first-line option. These findings require…
Two studies in The Lancet Oncology address the role of risk-reducing salpingo-oophorectomy and mastectomy to reduce the risk of ovarian and breast cancers in BRCA…
In this global cohort of BRCA carriers with previous breast cancer diagnosis at a young age, RRM and RRSO were both associated with a significant…
The evidence supports offering BSO to BRCA1 and BRCA2 pathogenic variant carrriers with a personal history of breast cancer, as they appear to benefit from…
The evidence supports offering BSO to BRCA1 and BRCA2 pathogenic variant carrriers with a personal history of breast cancer, as they appear to benefit from…
Good 6-month complete clinical responses rates were seen in both groups. Early results suggest rd-IMRT is well tolerated with oncological outcomes maintained. 3-year locoregional failure…
